21 CFR Part 211 is FDA's current good manufacturing practice (cGMP) regulation for finished pharmaceuticals. It sets minimum requirements for the people, facilities, equipment, components, production controls, packaging, laboratory testing, and records behind every drug product, and it gives the quality control unit the authority to approve or reject what goes into and out of production.
Who Part 211 applies to
Part 211 applies to the manufacturing, processing, packing, and holding of finished drug products for humans or animals, including OTC drugs and the CDMOs that make them under contract. Part 210 sets out the scope and definitions; Part 211 holds the requirements. Active pharmaceutical ingredients are held to cGMP through FDA's ICH Q7 guidance rather than Part 211 itself.
The full text is on the eCFR.
The 11 subparts at a glance
| Subpart | What it covers |
|---|---|
| A · General provisions | Scope and definitions |
| B · Organization and personnel | Quality control unit responsibilities, training, qualifications |
| C · Buildings and facilities | Design, lighting, ventilation, plumbing, sanitation |
| D · Equipment | Design, cleaning, maintenance, and automated or electronic equipment |
| E · Components, containers, and closures | Receipt, sampling, testing, approval or rejection |
| F · Production and process controls | Written procedures, deviations, in-process controls |
| G · Packaging and labeling control | Label control, packaging operations, expiration dating |
| H · Holding and distribution | Warehousing and distribution procedures |
| I · Laboratory controls | Specifications, testing, stability, reserve samples |
| J · Records and reports | Batch records, record review, complaints, annual review |
| K · Returned and salvaged drug products | Handling returned and salvaged product |
Where quality teams spend the most time
- Component testing (211.84): test each component lot for identity. You may rely on a supplier's certificate of analysis for other attributes only if you run at least one specific identity test and periodically validate the supplier's results. See the certificate of analysis guide.
- Written procedures and deviations (211.100): follow and document production and process control procedures, and record and justify any deviation from them.
- Production record review (211.192): review batch records before release and thoroughly investigate any unexplained discrepancy or specification failure, extending the investigation to other batches that may be affected. See deviation management.
- Complaint files (211.198): handle complaints under written procedures, with quality control unit review and a documented decision on whether to investigate.
- Annual product review (211.180(e)): review quality records for each product at least once a year to decide whether specifications or procedures need to change.
- Record retention (211.180): keep records at least one year after the batch's expiration date (three years after distribution for certain OTC products exempt from expiration dating).
How Part 211 relates to Part 11 and ICH Q10
When Part 211 records are kept electronically, 21 CFR Part 11 sets the rules for those electronic records and signatures. ICH Q10 is FDA-endorsed guidance describing a pharmaceutical quality system built on four elements: process performance and product quality monitoring, CAPA, change management, and management review.
Where Ovada fits
Ovada does the evidence-heavy work behind Part 211 records: comparing supplier CoAs with your specification, gathering records for investigations, drafting CAPAs, and monitoring procedures for changes. The quality control unit keeps every approval. See Ovada for pharmaceutical manufacturers.
Questions
What is the difference between 21 CFR Part 210 and Part 211?
Part 210 sets out the status, applicability, and definitions for the drug cGMP regulations. Part 211 contains the specific requirements for finished pharmaceuticals.
Does 21 CFR Part 211 apply to OTC drugs?
Yes. OTC drug products are finished pharmaceuticals and are subject to Part 211, with a few product-specific exemptions, such as the expiration dating exemption in 211.137 for certain stable OTC products.
How long must Part 211 records be kept?
At least one year after the expiration date of the batch, or three years after distribution for certain OTC products that are exempt from expiration dating.